Hermetica Superfood Encyclopedia
The Short Answer
Undaria galactofucan (UpG) is a sulfated heteropolysaccharide composed primarily of fucose and galactose that exerts antioxidant, anticancer, and anti-inflammatory effects by scavenging reactive oxygen species, suppressing pro-inflammatory cytokines, and disrupting tumor cell proliferation and migration pathways. In preclinical studies, purified UpG from U. pinnatifida sporophylls achieved IC50 values of 0.10 mg/mL against breast adenocarcinoma (MCF7) and 0.15 mg/mL against lung carcinoma cells, outperforming commercial Fucus-derived fucoidan in head-to-head comparisons.
CategoryExtract
GroupMarine-Derived
Evidence LevelPreliminary
Primary Keywordundaria galactofucan benefits
Undaria Galactofucan — botanical close-up
Health Benefits
**Anti-Tumor Activity**
Sulfated galactofucan inhibits cancer cell proliferation and migration in a dose-dependent manner (25–200 µg/mL range) in MCF7 breast adenocarcinoma and lung carcinoma cell lines, achieving IC50 values as low as 0.10 mg/mL while demonstrating selective cytotoxicity that spares non-malignant cells.
**Antioxidant Defense**
Low-molecular-weight fractions (<10 kDa) of UpG demonstrate potent DPPH radical scavenging equivalent to 1822.15 µg/mL Trolox equivalents and hydroxyl radical inhibition of 86.98%, with iron chelation reaching 73.55% at 500 µg/mL via interaction of sulfate and carboxyl groups with metal ions.
**Anti-Inflammatory Effects**
UpG suppresses key pro-inflammatory cytokines, reducing TNF-α by 39.7% and IL-1β by 47.08% at a concentration of 25 µg/mL, suggesting utility in conditions driven by chronic low-grade inflammation.
**Anticoagulant and Elastase Inhibition**
Galactofucan fractions inhibit elastase with an IC50 of 0.35 µg/mL, surpassing standard heparin preparations, and the sulfate groups at C-2, C-3, and C-4 positions of the fucopyranose backbone confer heparin-mimetic anticoagulant properties.
**Immunomodulation**
The sulfated polysaccharide backbone interacts with immune cell surface receptors to modulate innate immune responses, potentially enhancing macrophage and natural killer cell activity, though specific pathway data in human immune cells remains under investigation.
**FGF Pathway Inhibition**
UpG inhibits fibroblast growth factor (FGF) binding to cell surface receptors with IC50 values ranging from 4.0 to 93.5 µg/mL depending on fraction, a mechanism relevant to blocking angiogenesis and tumor vascularization.
**Biocompatibility as a Drug Delivery Matrix**
The high molecular weight fractions (up to 500 kDa) are biodegradable and biocompatible, supporting their investigation as scaffolds for targeted drug delivery systems in oncology and wound healing applications.
Origin & History
Natural habitat
Undaria pinnatifida, commonly known as wakame, is a brown macroalgae native to the cold coastal waters of Japan, Korea, and China, where it has been harvested for centuries from rocky subtidal zones. The seaweed thrives in nutrient-rich, temperate marine environments and is now commercially cultivated across Asia, as well as naturalized in parts of Europe, Australia, and North America. Galactofucan is concentrated particularly in the sporophylls (reproductive fronds) of the plant, which serve as a rich industrial source for polysaccharide extraction.
“Undaria pinnatifida has been consumed as wakame seaweed in Japanese, Korean, and Chinese culinary traditions for over a thousand years, featuring prominently in miso soup, seaweed salads, and medicinal tonic preparations documented in classical East Asian herbalism. In traditional Kampo (Japanese herbal medicine) and Korean folk medicine, wakame was valued broadly for nourishing the blood, supporting postpartum recovery, and promoting thyroid health, though these attributions were directed at the whole plant rather than any isolated polysaccharide fraction. The isolation and characterization of specific galactofucan polymers from U. pinnatifida is a modern scientific development, emerging from marine natural products chemistry research in the late 20th and early 21st centuries as analytical tools enabled structural elucidation of complex sulfated polysaccharides. Today, Japan and South Korea remain the primary producers of cultivated U. pinnatifida, where sporophylls—previously discarded as a processing byproduct—are now recognized as a concentrated source of bioactive galactofucans for nutraceutical and pharmaceutical research.”Traditional Medicine
Scientific Research
The current evidence base for Undaria galactofucan consists entirely of in vitro cell culture studies and, to a lesser extent, animal model experiments; no published human clinical trials with quantified sample sizes or effect sizes have been identified in the peer-reviewed literature. In vitro studies have systematically characterized structure-activity relationships, demonstrating that sulfation degree, molecular weight, and monosaccharide composition are key determinants of bioactivity, with low-MW (<10 kDa) fractions consistently showing superior antioxidant capacity and purified UpG outperforming commercial Fucus vesiculosus fucoidan in tumor cytotoxicity assays. Preclinical anti-inflammatory data showing 39.7% TNF-α and 47.08% IL-1β reduction at 25 µg/mL are promising but represent cell-free or monocyte-based assay conditions that do not predict in vivo dose-response relationships. Overall, the evidence is classified as preliminary-to-preclinical, and translation to validated therapeutic claims requires pharmacokinetic studies, animal efficacy trials with standardized endpoints, and ultimately randomized controlled human trials.
Preparation & Dosage
Traditional preparation
**Crude Aqueous Extract**
Prepared by hot-water or mild acid extraction of dried U. pinnatifida sporophylls; concentration and purity vary widely; no established human dose.
**Purified Galactofucan Polysaccharide (UpG)**
Obtained via CaCl2 precipitation followed by NaCl gradient elution (1.3 mol/L) and Sephacryl S-400 size-exclusion chromatography, yielding a 97.9 kDa fraction; used at 25–500 µg/mL in vitro.
**Low-Molecular-Weight Fraction (<10 kDa)**
Produced by controlled acid hydrolysis or enzymatic degradation of high-MW UpG; demonstrates superior DPPH scavenging and bioavailability potential due to enhanced aqueous solubility.
**Standardized Fucoidan Supplement (commercial analogue)**
300 mg to 4 g/day, though these data are not specific to isolated galactofucan
Commercially available fucoidan products derived from U. pinnatifida are typically standardized to ≥85% polysaccharide content; empirical human doses in fucoidan literature range from .
**Timing and Form Note**
No clinical pharmacokinetic data establish optimal timing; oral bioavailability of high-MW fractions is presumed to be limited by intestinal mucosal barriers, suggesting low-MW or modified forms may be more appropriate for systemic delivery.
Nutritional Profile
As a marine polysaccharide extract, Undaria galactofucan in its purified form is predominantly carbohydrate (>85% polysaccharide by dry weight in standardized preparations), with negligible protein, fat, or caloric content in isolated fractions. The key phytochemical constituents are sulfated galactofucan polymers characterized by a fucose:glucose:galactose molar ratio of approximately 27.15:19.34:53.51 and sulfate content up to 25.19% by weight, alongside minor constituents including mannose, xylose, and uronic acids. The whole seaweed additionally provides iodine (critical for thyroid function), magnesium, calcium, folate, and the carotenoid fucoxanthin, though these are not retained in purified galactofucan extracts. Bioavailability of the polysaccharide is inversely related to molecular weight; fractions below 10 kDa demonstrate superior aqueous solubility and presumed intestinal permeability compared to native high-MW polymers exceeding 100 kDa.
How It Works
Mechanism of Action
Undaria galactofucan's backbone of α-(1→3)/(1→4)-L-fucopyranose with β-(1→6)-D-galactopyranose branches, combined with sulfation levels up to 25.19%, enables multivalent interactions with proteins, receptors, and metal ions central to its bioactivity. Its antioxidant mechanism involves direct hydrogen atom donation from hydroxyl groups to neutralize DPPH and hydroxyl radicals, while sulfate and carboxyl moieties chelate pro-oxidant transition metals such as iron and copper, thereby attenuating Fenton-type ROS generation. Anticancer activity is mediated by disruption of cell survival signaling cascades—including pathways governing proliferation, migration, and apoptosis resistance—in malignant cells, with structural sulfation density appearing to dictate binding affinity to growth factor receptors such as FGFRs, effectively blocking ligand-receptor interaction and downstream angiogenic signaling. Anti-inflammatory action proceeds through suppression of NF-κB-dependent cytokine transcription, reducing secretion of TNF-α and IL-1β, while elastase inhibition suggests additional modulation of the proteolytic microenvironment associated with inflammatory tissue remodeling.
Clinical Evidence
No human clinical trials have been conducted specifically on Undaria galactofucan (UpG) as an isolated compound; available data derive exclusively from in vitro and limited animal studies. The strongest preclinical signals relate to anticancer cytotoxicity, with IC50 values of 0.10 mg/mL (breast adenocarcinoma) and 0.15 mg/mL (lung carcinoma), and to anti-inflammatory cytokine suppression at concentrations achievable in cell culture systems. Confidence in these results is constrained by the absence of pharmacokinetic data confirming that bioactive concentrations can be achieved in human plasma or tumor tissue following oral supplementation. Until well-designed phase I/II trials establish safety, tolerability, and preliminary efficacy endpoints, UpG should be regarded as a bioactive research compound with significant therapeutic promise rather than a clinically validated intervention.
Safety & Interactions
Purified Undaria galactofucan has demonstrated low cytotoxicity and high biocompatibility in cell-based assays, with selective toxicity toward malignant rather than normal cells, and no specific adverse effects have been reported in the available preclinical literature. However, the sulfate groups characteristic of galactofucans and structurally related fucoidans confer heparin-mimetic properties, raising a clinically important concern for additive bleeding risk in patients taking anticoagulant or antiplatelet medications such as warfarin, heparin, aspirin, or direct oral anticoagulants (DOACs). No formal toxicology studies, maximum tolerated dose data, or reproductive safety data specific to isolated UpG have been published, making guidance for pregnant or lactating individuals impossible beyond a general precautionary recommendation to avoid use until safety is established. Given the absence of human pharmacovigilance data, individuals with clotting disorders, those scheduled for surgery, and patients on immunosuppressive therapies should consult a healthcare provider before use.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Undaria pinnatifidaWakame galactofucanUpGSulfated galactofucanFucoidan variant (Undaria)Wakame polysaccharide
Frequently Asked Questions
What is Undaria galactofucan and how does it differ from regular fucoidan?
Undaria galactofucan (UpG) is a sulfated heteropolysaccharide extracted from Undaria pinnatifida (wakame) seaweed, composed primarily of galactose and fucose in a roughly 53:27 molar ratio, which distinguishes it from the predominantly fucose-based fucoidans derived from Fucus vesiculosus. The higher galactose content and distinct sulfation pattern at C-2, C-3, and C-4 positions of the fucopyranose backbone give UpG superior cytotoxicity against breast adenocarcinoma (IC50 0.10 mg/mL) compared to commercial Fucus fucoidan in direct comparisons. This structural uniqueness also contributes to its notably potent elastase inhibition (IC50 0.35 µg/mL), a property not widely reported for standard fucoidan products.
What does the research say about Undaria galactofucan for cancer?
Current research on Undaria galactofucan's anticancer properties is limited to in vitro (cell culture) studies; no human clinical trials have been published. Purified UpG from U. pinnatifida sporophylls inhibited MCF7 breast adenocarcinoma cells with an IC50 of 0.10 mg/mL and lung carcinoma cells at 0.15 mg/mL, with activity attributed to disruption of cell proliferation, migration, and FGF receptor signaling at concentrations of 25–200 µg/mL. These results are promising but cannot be extrapolated to human therapeutic outcomes without pharmacokinetic and clinical trial data.
Is Undaria galactofucan safe to take as a supplement?
Based on preclinical evidence, purified Undaria galactofucan is considered biocompatible and low in toxicity, with demonstrated selectivity for cancer cells over normal cells in laboratory assays. However, its sulfate groups mimic heparin structurally, which raises a significant interaction concern with anticoagulant and antiplatelet drugs—including warfarin, aspirin, and DOACs—potentially increasing bleeding risk. No formal human safety or toxicology trials have been conducted, so individuals with coagulation disorders, pregnant or breastfeeding women, or those on blood-thinning medications should avoid use without medical supervision.
What dose of Undaria galactofucan is effective?
No standardized human supplemental dose has been established for isolated Undaria galactofucan, as all dose-response data come from in vitro studies using concentrations of 25–500 µg/mL in cell culture systems. Commercially available U. pinnatifida fucoidan supplements (which contain galactofucan as a component) are generally used at empirical doses of 300 mg to 4 g per day in human fucoidan research, though these figures are not specific to purified UpG. Low-molecular-weight fractions (<10 kDa) are hypothesized to offer better oral bioavailability, but clinical pharmacokinetic studies confirming effective plasma concentrations have not been published.
What are the antioxidant properties of Undaria galactofucan?
Undaria galactofucan, particularly its low-molecular-weight fractions (<10 kDa), demonstrates strong antioxidant activity across multiple assay models: DPPH radical scavenging equivalent to 1822.15 µg/mL Trolox equivalents, hydroxyl radical inhibition of 86.98%, and iron chelation of 73.55% at 500 µg/mL. These effects are driven by the hydroxyl groups donating hydrogen atoms to neutralize free radicals and the sulfate and carboxyl groups binding pro-oxidant metal ions, thereby preventing Fenton-type ROS amplification. Higher sulfation content and lower molecular weight consistently correlate with greater antioxidant potency across characterized fractions.
Does Undaria galactofucan interact with chemotherapy or cancer medications?
Undaria galactofucan shows promising synergistic potential with certain chemotherapy approaches in laboratory studies, though human clinical data on drug interactions remains limited. Because it demonstrates selective cytotoxicity toward cancer cells while sparing healthy cells, it may theoretically complement conventional treatments, but anyone undergoing cancer therapy should consult their oncologist before adding this supplement. Current evidence does not indicate major interactions with standard medications, but individual cases should be evaluated by a healthcare provider familiar with both the supplement and the patient's treatment regimen.
What form of Undaria galactofucan extract is most effective for absorption?
Low-molecular-weight fractions (below 10 kDa) of Undaria galactofucan demonstrate superior bioavailability and antioxidant activity compared to higher-molecular-weight forms, making them preferable for systemic absorption. Extraction methods that preserve the sulfated structure of the polysaccharide are critical, as the degree of sulfation directly influences both potency and cellular uptake. Standardized extracts guaranteeing molecular weight distribution and sulfation levels provide more consistent results than crude seaweed powders.
Who would benefit most from taking Undaria galactofucan supplementation?
Individuals seeking enhanced antioxidant defense and those interested in natural cancer-preventive compounds represent the primary beneficiary groups, particularly those with family history of breast or lung cancer based on current research. People with compromised immune systems or oxidative stress-related conditions may also derive benefit from its dual antioxidant and immunomodulatory properties. Those already consuming wakame seaweed regularly may receive additional concentrated benefit from a standardized extract form, though dietary sources alone provide meaningful levels of related fucoidan compounds.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w undaria-galactofucan-undaria-pinnatifida curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
